Expert Interview
Third View: Discussing Arvinas' Phase 1 trial for PROTACT ARV-102, an oral medication demonstrating blood-brain barrier penetration, and central and peripheral LRRK2 degradation.
Ticker(s): ARVNInstitution: Neurology Center of Nevada
- Board certified and fellowship trained Movement Disorders Neurologist.
- Specializes in the diagnosis and management of Parkinson's Disease, atypicalparkinsonism (PSP, MSA, DLB), essential tremor, dystonia, myoclonus, ataxia, chorea,tardive syndromes, restless leg syndrome, tourette's/tic disorders,
- Also expertly trained in Deep Brain Stimulation (DBS)programming and botulinum toxin (botox) injections for migraine, dystonia, andspasticity.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
